Routine melanoma-focused next-generation sequencing (NGS) panels do not typically include CRTC1 or TRIM11, so diagnosis often requires targeted RNA sequencing or fusion-based NGS assays [2]. This evidence concerns the gene TRIM11 and melanoma.